# A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants

> **NCT05057949** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Larotinib
- **DRUG:** Rifampin
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT05057949
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2022-02-17
- **Final completion:** 2023-09-28
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057949, "A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05057949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*